OptiNose (OPTN) Getting Somewhat Favorable Media Coverage, Study Shows

News stories about OptiNose (NASDAQ:OPTN) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OptiNose earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8081992855721 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

OptiNose (NASDAQ OPTN) opened at $18.95 on Monday. OptiNose has a one year low of $15.01 and a one year high of $21.46.

OPTN has been the topic of a number of research analyst reports. Jefferies Group initiated coverage on shares of OptiNose in a report on Tuesday, November 7th. They set a “buy” rating and a $27.00 price objective on the stock. BMO Capital Markets initiated coverage on shares of OptiNose in a report on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price objective on the stock. Royal Bank of Canada initiated coverage on shares of OptiNose in a report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, Piper Jaffray Companies started coverage on shares of OptiNose in a report on Tuesday, November 7th. They set an “overweight” rating and a $27.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: “OptiNose (OPTN) Getting Somewhat Favorable Media Coverage, Study Shows” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/18/optinose-optn-getting-somewhat-favorable-media-coverage-study-shows.html.

About OptiNose

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Insider Buying and Selling by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply